Halper Sadeh LLC said it is investigating whether certain officers and directors of Metagenomi Therapeutics, Inc. (NASDAQ: MGX) breached their fiduciary duties to shareholders. The Aug. 25, 2026, announcement urged current long-term Metagenomi shareholders to discuss their rights and options at no cost or obligation, while warning that there may be limited time to enforce their rights. Potential remedies could include corporate governance reforms, the return of funds to Metagenomi, a court-approved financial incentive award, or other relief and benefits. The firm said any matter would be handled on a contingent fee basis, with shareholders not responsible for out-of-pocket legal fees or expenses. It said shareholder participation can support stronger policies, oversight and accountability, potentially enhancing shareholder value.